Search results for "Statin"

showing 10 items of 545 documents

Myostatin/activin blocking combined with exercise reconditions skeletal muscle expression profile of mdx mice

2015

Duchenne Muscular Dystrophy is characterized by muscle wasting and decreased aerobic metabolism. Exercise and blocking of myostatin/activin signaling may independently or combined counteract muscle wasting and dystrophies. The effects of myostatin/activin blocking using soluble activin receptor-Fc (sActRIIB-Fc) administration and wheel running were tested alone or in combination for seven weeks in dystrophic mdx mice. Expression microarray analysis revealed decreased aerobic metabolism in the gastrocnemius muscle of mdx mice compared to healthy mice. This was not due to reduced home-cage physical activity, and was further downregulated upon sActRIIB-Fc treatment in enlarged muscles. However…

muscular dystrophymedicine.medical_specialtyDuchenne muscular dystrophyActivin Receptors Type IIRecombinant Fusion Proteinsphysical activityMyostatinBiologyta3111BiochemistryMuscle hypertrophy03 medical and health sciencesGastrocnemius muscleMice0302 clinical medicineEndocrinologyoxidative metabolismInternal medicinePhysical Conditioning AnimalGene expressionmedicineSTAT5 Transcription FactorAnimalsmuscle hypertrophyMuscular dystrophyPhosphorylationta315Muscle SkeletalMolecular BiologyWasting030304 developmental biologyInhibin-beta Subunits0303 health sciencesPhysical activitySkeletal muscleMyostatinmusculoskeletal systemmedicine.diseaseMuscular dystrophymRNA profilingEndocrinologymedicine.anatomical_structurebiology.proteinMice Inbred mdxOxidative metabolismMuscle hypertrophymedicine.symptom030217 neurology & neurosurgery
researchProduct

<p>Effects of losartan and atorvastatin on the development of early posttraumatic joint stiffness in a rat model</p>

2019

Background After a trauma, exuberant tissue healing with fibrosis of the joint capsule can lead to posttraumatic joint stiffness (PTJS). Losartan and atorvastatin have both shown their antifibrotic effects in different organ systems. Objective The purpose of this study was the evaluation of the influence of losartan and atorvastatin on the early development of joint contracture. In addition to joint angles, the change in myofibroblast numbers and the distribution of bone sialoprotein (BSP) were assessed. Study design and methods In this randomized and blinded experimental study with 24 rats, losartan and atorvastatin were compared to a placebo. After an initial joint injury, rat knees were …

musculoskeletal diseases0301 basic medicinePharmacologymedicine.medical_specialtyArticular capsule of the knee jointbusiness.industryAtorvastatinUrologyPharmaceutical SciencePlacebo03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureLosartan030220 oncology & carcinogenesisJoint stiffnessDrug DiscoveryJoint capsulemedicineJoint Contracturemedicine.symptomContracturebusinessmedicine.drugDrug Design, Development and Therapy
researchProduct

Case Report: Unmasking Hypercalcemia in Patients With Neuroendocrine Neoplasms. Experience From Six Italian Referral Centers

2021

BackgroundHypercalcemia is a common paraneoplastic syndrome which can occur in up to 10% of patients with advanced neoplasms. Paraneoplastic parathyroid hormone-related protein (PTHrP) represents the most frequent cause of this syndrome. In neuroendocrine neoplasms (NENs) paraneoplastic hypercalcemia is rare.Case SeriesThe present series includes all patients with NENs and paraneoplastic hypercalcemia from four Italian centres: (I) A 40-year-old man was hospitalized for repeated episodes of falls, hyposthenia and drowsiness. Severe hypercalcemia was found. Metastatic pancreatic G2 NEN and PTHrP-related hypercalcemia were diagnosed. The patient started therapy with somatostatin analogs (SSA)…

musculoskeletal diseasesAdultMalemedicine.medical_specialty125-dihydroxyvitamin Dbronchial carcinoidEndocrinology Diabetes and Metabolism1pancreatic NENCase ReportGastroenterologyDiseases of the endocrine glands. Clinical endocrinologyparaneoplastic hypercalcemia; parathyroid hormone-related protein; pancreatic nen; bronchial carcinoid; 125-dihydroxyvitamin dEndocrinologyparaneoplastic hypercalcemiaInternal medicinemedicineHumansVitamin DAgedEverolimusmedicine.diagnostic_testPerformance statusParathyroid hormone-related proteinbusiness.industryparathyroid hormone-related proteinMiddle AgedRC648-665PrognosisPancreatic NeoplasmsNeuroendocrine TumorsSomatostatinDenosumabPositron emission tomographyCalcitoninRadionuclide therapyHypercalcemiaFemalebusiness25-dihydroxyvitamin dhormones hormone substitutes and hormone antagonistsmedicine.drugFrontiers in Endocrinology
researchProduct

Combined effect of AAV-U7-induced dystrophin exon skipping and soluble activin Type IIB receptor in mdx mice.

2012

Adeno-associated virus (AAV)-U7-mediated skipping of dystrophin-exon-23 restores dystrophin expression and muscle function in the mdx mouse model of Duchenne muscular dystrophy. Soluble activin receptor IIB (sActRIIB-Fc) inhibits signaling of myostatin and homologous molecules and increases muscle mass and function of wild-type and mdx mice. We hypothesized that combined treatment with AAV-U7 and sActRIIB-Fc may synergistically improve mdx muscle function. Bioactivity of sActRIIB-Fc on skeletal muscle was first demonstrated in wild-type mice. In mdx mice we show that AAV-U7-mediated dystrophin restoration improved specific muscle force and resistance to eccentric contractions when applied a…

musculoskeletal diseasesmdx mousemedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesDuchenne muscular dystrophyActivin Receptors Type IIGenetic VectorsMyostatinBiologyDystrophin03 medical and health sciencesMice0302 clinical medicineInternal medicineGeneticsmedicineMyocyteAnimalsMuscular dystrophyMuscle SkeletalMolecular Biology030304 developmental biology0303 health sciencesBody WeightSkeletal muscleExonsGenetic TherapyDependovirusMuscular Dystrophy Animalmedicine.diseasemusculoskeletal system3. Good healthMice Inbred C57BLEndocrinologymedicine.anatomical_structureImmunologybiology.proteinMice Inbred mdxMolecular MedicineITGA7Dystrophin030217 neurology & neurosurgeryMuscle ContractionHuman gene therapy
researchProduct

Inhibition of xanthine oxidase to prevent statin-induced myalgia and rhabdomiolysis

2015

Although statins remain the cornerstone of lipid-lowering therapy for reducing the burden of atherosclerotic vascular disease, their administration has been associated with muscle-related adverse effects, including myalgia and rhabdomyolysis. Such adverse events are probably due to reduced antioxidant defenses associated with fewer intermediate metabolites in the cholesterol synthesis pathway. We hypothesize that the concomitant inhibition of xanthine oxidase via coadministration of allopurinol with statins could diminish reactive oxygen species (ROS)-related muscle damage, which would have in turn have positive effects on both the incidence of muscle-related adverse events and cardiovascul…

myalgiaXanthine OxidaseAntioxidantStatinUbiquinonemedicine.drug_classAllopurinolmedicine.medical_treatmentHypercholesterolemiaAllopurinolPharmacologyRhabdomyolysischemistry.chemical_compoundAnimalsHumansMedicineXanthine oxidaseEnzyme InhibitorsXanthine oxidaseAdverse effectchemistry.chemical_classificationReactive oxygen speciesLipid-lowering drugsbusiness.industryMyalgiamedicine.diseasechemistryCardiovascular DiseasesHydroxymethylglutaryl-CoA Reductase Inhibitorsmedicine.symptomReactive Oxygen SpeciesCardiology and Cardiovascular MedicinebusinessRhabdomyolysisBiomarkersmedicine.drugAtherosclerosis
researchProduct

Management of Statin Intolerance in 2018: Still More Questions Than Answers.

2018

Statin therapy is generally well tolerated and very effective in the prevention and treatment of cardiovascular disease, regardless of cholesterol levels; however, it can be associated with various adverse events (myalgia, myopathy, rhabdomyolysis, and diabetes mellitus, among others). Patients frequently discontinue statin therapy without medical advice because of perceived side effects and consequently increase their risk for cardiovascular events. In patients with statin intolerance, it may be advisable to change the dose, switch to a different statin, or try an alternate-day regimen. If intolerance is associated with all statins—even at the lowest dose—non-statin drugs and certain nutra…

myalgiamedicine.medical_specialtyStatinDrug-Related Side Effects and Adverse Reactionsmedicine.drug_classDiseaseReview Article030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePharmacotherapyMedical adviceDiabetes mellitusCardiovascular DiseasemedicineHumansPharmacology (medical)030212 general & internal medicinecardiovascular diseasesAdverse effectIntensive care medicineDietary SupplementHypolipidemic AgentsHypolipidemic Agentbusiness.industrynutritional and metabolic diseasesDisease ManagementGeneral MedicineCholesterol LDLmedicine.diseaseRegimenCardiovascular DiseasesDietary Supplementslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitormedicine.symptomHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessDrug-Related Side Effects and Adverse ReactionHumanAmerican journal of cardiovascular drugs : drugs, devices, and other interventions
researchProduct

Analysis of vitamin D levels in patients with and without statin-associated myalgia — A systematic review and meta-analysis of 7 studies with 2420 pa…

2014

article i nfo Introduction: VitaminD (vitD)deficiencymay beassociatedwith anincreased riskof statin-related symptomatic myalgia in statin-treated patients. The aim of this meta-analysis was to substantiate the role of serum vitamin D levels in statin-associated myalgia. Methods: The search included PUBMED, Cochrane Library, Scopus, and EMBASE from January 1, 1987 to April 1, 2014 to identify studies that investigated the impact of vit D levels in statin-treated subjects with and without myalgia. Two independent reviewers extracted data on study characteristics, methods and outcomes. Quantita- tive data synthesis was performed using a fixed-effect model. Results: The electronic search yielde…

myalgiamedicine.medical_specialtyStatinmedicine.drug_classCochrane LibraryAsymptomaticGastroenterologylaw.inventionRandomized controlled triallawInternal medicinemedicineVitamin D and neurologyHumansVitamin Dbusiness.industryMyalgiaConfidence intervalSurgeryObservational Studies as TopicMeta-analysisHydroxymethylglutaryl-CoA Reductase Inhibitorsmedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersInternational Journal of Cardiology
researchProduct

Abstract 18967: Analysis of Vitamin D Levels in Patients With and Without Statin-induced Myalgia - A Systematic Review and Meta-analysis of 7 Studies…

2014

Introduction: Vitamin D (vit D) deficiency may be associated with an increased risk of statin-related muscle complaints, and symptomatic myalgia in statin-treated patients. Hypothesis: The aim of this meta-analysis was to investigate whether subjects with statin-induced myalgia have lower serum vit D levels compared with those who are asymptomatic. Methods: We searched PubMed, Web of Science, Cochrane Library, Scopus and EMBASE (up to March 2014) to identify studies that investigated the impact of vit D levels in statin-treated subjects with and without myalgia. Two independent reviewers extracted data on study characteristics, methods and outcomes. Results: The electronic search yielded 4…

myalgiamedicine.medical_specialtyStatinmedicine.drug_classbusiness.industryCochrane Librarymedicine.diseaseAsymptomaticGastroenterologyvitamin D deficiencySurgerylaw.inventionRandomized controlled triallawPhysiology (medical)Internal medicineMeta-analysismedicineVitamin D and neurologymedicine.symptomCardiology and Cardiovascular MedicinebusinessCirculation
researchProduct

Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis.

2003

Inflammation underlies both onset and perpetuation of atherosclerosis. Plasma lipoproteins transport the platelet-activating factor-acetylhydrolase (PAF-AH) with potentially anti-inflammatory activities. Our aim was to determine whether PAF-AH activity was associated with inflammatory markers and with coronary artery disease (CAD). PAF-AH activity and a panel of inflammatory mediators were measured in plasma of 496 patients with CAD and in 477 controls; 276 patients presented with stable angina pectoris and 220 with acute coronary syndrome (ACS). Individuals within the highest quartile of PAF-AH activity had an 1.8-fold increase in CAD risk [95% confidence interval (CI), 1.01 to 3.2; P = 0.…

platelet-activating factorAdultMaleRiskmedicine.medical_specialtyAcute coronary syndromePAF acetylhydrolaseStatinCross-sectional studymedicine.drug_classMutation MissenseInflammationAngiotensin-Converting Enzyme InhibitorsQD415-436Coronary Artery DiseaseBiochemistryCoronary artery diseaseEndocrinologySex FactorsRisk FactorsInternal medicinemedicineHumansAgedInflammationbusiness.industryCell BiologySyndromeMiddle Agedmedicine.diseaseConfidence intervalCross-Sectional StudiesQuartile1-Alkyl-2-acetylglycerophosphocholine EsteraseAcute DiseaseCardiologylipids (amino acids peptides and proteins)Femaleatherosclerosismedicine.symptombusinessJournal of lipid research
researchProduct

Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity

2011

Normal tissue damage limits the efficacy of anticancer therapy. For anthracyclines, the clinically most relevant adverse effect is cardiotoxicity. The mechanisms involved are poorly understood and putative cardioprotectants are controversially discussed. Here, we show that the lipid-lowering drug lovastatin protects rat H9c2 cardiomyoblasts from doxorubicin in vitro. Protection by lovastatin is related to inhibition of the Ras-homologous GTPase Rac1. It rests on a reduced formation of DNA double-strand breaks, resulting from the inhibition of topoisomerase II by doxorubicin. Doxorubicin transport and reactive oxygen species are not involved. Protection by lovastatin was confirmed in vivo. I…

rac1 GTP-Binding ProteinCancer ResearchAnthracyclineDoxorubicin transportCardiac fibrosismedicine.medical_treatmentImmunologyPharmacologyBiologyDNA damage responsestatinsMiceCellular and Molecular NeuroscienceRho GTPasespolycyclic compoundsmedicineAnimalsDNA Breaks Double-StrandedMyocytes CardiacDoxorubicinLovastatinanthracyclinesCardiotoxicityAntibiotics AntineoplasticTroponin IConnective Tissue Growth FactorCell Biologymedicine.diseaseRatsCTGFDNA Topoisomerases Type IICytokinenormal tissue damageDoxorubicinOriginal Articlelipids (amino acids peptides and proteins)LovastatinAtrial Natriuretic FactorSignal Transductionmedicine.drugCell Death & Disease
researchProduct